Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.

Journal: Cancer Cell

Published: 2018-12-10

DOI: 10.1016/j.ccell.2018.11.007

Affiliations: 24

Authors: 35

Go to article
Institutions FC
Department of Molecular and Cellular Oncology, MD Anderson Cancer Center, United States of America (USA) 0.53
Department of Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, United States of America (USA) 0.09
Taoyuan Chang Gung Memorial Hospital, Chang Gung Medical Foundation, Taiwan 0.04
Chang Gung Medical Foundation, Taiwan 0.04
Research Center for Tumor Medical Science (TMS), CMU, Taiwan 0.04
China Medical University Hospital (CMUH), Taiwan 0.04
Center for Molecular Medicine, CMU, Taiwan 0.03
State Key Laboratory of Oncology in South China, SYSU, China 0.03
Graduate Institute of Biomedical Sciences, CMU, Taiwan 0.02
NYU Laura and Isaac Perlmutter Cancer Center, United States of America (USA) 0.02
Department of Biotechnology, Asia University, Taiwan 0.02
Department of Medical Oncology, DFCI, United States of America (USA) 0.02
Department of Pathology, CGU, Taiwan 0.02
Harbin Medical University Cancer Hospital, China 0.01
College of Medicine, CGU, Taiwan 0.01
Kaohsiung Chang Gung Memorial Hospital, Chang Gung Medical Foundation, Taiwan 0.01
Robert and Renée Belfer Center for Applied Cancer Science (The Belfer Center), DFCI, United States of America (USA) 0.01
College of Health Care, CMU, Taiwan 0.01
Department of Physics, NCHU, Taiwan 0.01

Return